Abstract
Coronary slow flow (CSF) phenomenon, which is characterized by delayed opacification of epicardial coronary arteries in the absence of stenotic lesion, is a relatively common finding in patients undergoing routine coronary angiography and is often associated with chest pain. There are no definite treatment modalities for patients with CSF to date, and conventional antianginal therapy is of limited value in the chronic management of these patients. Enhanced external counterpulsation (EECP) has become one of the most effective noninvasive treatment methods for patients with refractory angina [1], and has been considered a new modality in management of cardiac syndrome X [2,3], whether it is effective for treating CSF remains unclear.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
